Bolt Net Income From Continuing Ops from 2010 to 2026
| BOLT Stock | USD 4.95 0.03 0.61% |
Net Loss | First Reported 2019-12-31 | Previous Quarter -8.6 M | Current Value -7.1 M | Quarterly Volatility 6.7 M |
Check Bolt Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bolt Biotherapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 6.3 M, Interest Income of 6.3 M or Depreciation And Amortization of 1.2 M, as well as many indicators such as Price To Sales Ratio of 58.04, Dividend Yield of 0.0 or PTB Ratio of 6.75. Bolt financial statements analysis is a perfect complement when working with Bolt Biotherapeutics Valuation or Volatility modules.
Bolt | Net Income From Continuing Ops | Build AI portfolio with Bolt Stock |
The evolution of Net Income From Continuing Ops for Bolt Biotherapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Bolt Biotherapeutics compares to historical norms and industry peers.
Latest Bolt Biotherapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Bolt Biotherapeutics over the last few years. It is Bolt Biotherapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bolt Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Bolt Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (37,239,218) | |
| Coefficient Of Variation | (83.81) | |
| Mean Deviation | 27,953,433 | |
| Median | (11,589,000) | |
| Standard Deviation | 31,208,537 | |
| Sample Variance | 974T | |
| Range | 87M | |
| R-Value | (0.79) | |
| Mean Square Error | 390T | |
| R-Squared | 0.62 | |
| Significance | 0.0002 | |
| Slope | (4,884,516) | |
| Total Sum of Squares | 15583.6T |
Bolt Net Income From Continuing Ops History
About Bolt Biotherapeutics Financial Statements
Bolt Biotherapeutics shareholders use historical fundamental indicators, such as Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Bolt Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Bolt Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Bolt Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -56.8 M | -59.6 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.